drugset / Trial / NCT00605319

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

NCT00605319

NaSingle-groupOpen-labelTreatment

Summary

The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.

Timeline

Start
2010-01
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg Oral
Subject Fesoterodine Other / unclassified 8 mg Oral